Stevens–Johnson syndrome after treatment with STI571: a case report

Hsiao, Liang Tsai; Chung, Hung Ming; Lin, Jui-Wei; Chiou, Tzeon Jye; Liu, Jin Hwang; Fan, Frank S.; Wang, Wei Shu; Yen, Chueh Chuan; Chen, Po Min

doi:10.1046/j.1365-2141.2002.03499.x

Cited by 96 publications

(55 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three cases of acute generalized exanthematous pustulosis have been reported, as well as two cases of Stevens-Johnson syndrome, both in patients receiving imatinib for treatment of blast-crisis CML [40,[46][47][48]. One case each of pityriasis rosea and oral lichenoid reaction, possibly related to imatinib treatment, have also been described [49,50].…”

Section: Cutaneous Reactionsmentioning

confidence: 99%

Indications for Imatinib Mesylate Therapy and Clinical Management

2004

View full text Add to dashboard Cite

Imatinib mesylate (Gleevec ® , Glivec ® , formerly STI571; Novartis Pharma AG; Basel, Switzerland) is a rationally-designed, molecularly-specific oral anticancer agent that selectively inhibits several protein tyrosine kinases central to the pathogenesis of human cancer. It has demonstrated remarkable clinical efficacy in patients with chronic myeloid leukemia and malignant gastrointestinal stromal tumors. Treatment with imatinib is generally well tolerated, and the risk for severe adverse effects is low. Adverse effects most commonly include mild-to-moderate edema, nausea and vomiting, diarrhea, muscle cramps, and cutaneous reactions. Hepatic transaminase level elevations and myelosuppression occur less frequently and resolve with interruption of imatinib therapy. In general, the incidence and severity of adverse effects tend to correlate with imatinib dose and, in chronic myeloid leukemia patients, the phase of disease; but, patient age and other factors are also associated with some types of reactions. With prompt and appropriate intervention, adverse effects in imatinib-treated patients have proven to be manageable across the spectrum of severity, and they seldom require permanent cessation of therapy. Dose reduction is not usually necessary, and reduction to subtherapeutic levels is not recommended.

show abstract

Section: Cutaneous Reactionsmentioning

confidence: 99%

Indications for Imatinib Mesylate Therapy and Clinical Management

2004

View full text Add to dashboard Cite

show abstract

“…Skin rashes are seen in about one-third of patients. They vary greatly in appearance, and may be quite severe, with one patient developing Stevens-Johnson syndrome (Hsiao et al, 2002). Most of the rashes are mild and self-limited or respond to antihistamines or steroids.…”

Section: Nonhematological Toxicity a Edema And Fluidmentioning

confidence: 99%

Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib

2003

View full text Add to dashboard Cite

“…Erythema multiforme is a severe adverse cutaneous reaction producing important morbidity. 7,8 In patients treated with imatinib, 7% to 21% suffer adverse cutaneous reactions. 9 This incidence appears to be dose-dependent, and 5% of such reactions are severe or life-threatening.…”

mentioning

confidence: 99%